Is Lounge Membership Still Worth It in 2025? There is a certain romance in airport lounges, a feeling of escaping the chaos ...

The issue with placing it on the floodplain is that it reduces the available area for floodwaters to spread out and slow down,” one neighbor said.

Kura Oncology missed GAAP revenue estimates in Q2 2025. Ziftomenib advanced to FDA Priority Review, hitting key clinical and regulatory milestones, with no product sales yet. Research and ...

QNRX READ THE FULL QNRX RESEARCH REPORT FDA clears initiation of 2nd NS pivotal whole body clinical study for QRX003, CL-QRX003-002 Quoin Pharmaceuticals (NASDAQ:QNRX) reported 2Q25 results today and ...

COPENHAGEN - Ascendis Pharma A/S (NASDAQ: ASND) shares gained 2.9% after the biopharmaceutical company reported a narrower-than-expected second-quarter loss and revenue that exceeded analyst estimates ...

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Wessex, which missed out on the devolution priority programme, has announced a number steps locally to lay the groundwork for ...

Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.

Explore how Whitehorse’s 2025–2028 Strategic Priorities address urgent housing needs, streamline permitting, modernize zoning ...

MSU is pausing a 'transition of psychiatric services for students,' apparently in response to pushback to layoffs of staff ...

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 ...

Comprehensive ecommerce platform with advanced features and multi-store capability — but watch out for limited free themes and editor quirks.